MTARC1 (mitochondrial amidoxime reducing component 1)

2014-11-01  

Identity

HGNC
MTARC1
LOCATION
1q41
LOCUSID
64757
ALIAS
MARC1,MOSC1

Other Information

Locus ID:

NCBI: 64757
MIM: 614126
HGNC: 26189
Ensembl: ENSG00000186205

Variants:

dbSNP: 64757
ClinVar: 64757
TCGA: ENSG00000186205
COSMIC: MTARC1

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000186205ENST00000366910Q5VT66
ENSG00000186205ENST00000407981H7BYZ9
ENSG00000186205ENST00000443880X6RIL1
ENSG00000186205ENST00000463976H0YDX4

Pathways

PathwaySourceExternal ID
MetabolismREACTOMER-HSA-1430728
Biological oxidationsREACTOMER-HSA-211859
Phase 1 - Functionalization of compoundsREACTOMER-HSA-211945

References

Pubmed IDYearTitleCitations
383406542024Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.1
383759852024Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.2
384372272024Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.1
386194292024mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.0
387237512024Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1.0
383406542024Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.1
383759852024Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.2
384372272024Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.1
386194292024mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.0
387237512024Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1.0
354116672022Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.15
362331172022Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men.2
365554672022MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery.5
354116672022Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.15
362331172022Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men.2

Citation

Dessen P

MTARC1 (mitochondrial amidoxime reducing component 1)

Atlas Genet Cytogenet Oncol Haematol. 2014-11-01

Online version: http://atlasgeneticsoncology.org/gene/68804/mtarc1-(mitochondrial-amidoxime-reducing-component-1)